SCHEMBL23588190

SCHEMBL23588190

CCCCOc1ccc(-c2noc(/C=C(\C)C(=O)O)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 3/20 0.50
▸ ACACA Q13085 1/20 0.48
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ TP53 P04637 2/20 0.46
▸ MITF O75030 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ S1PR1 P21453 1/20 0.46
▸ S1PR3 Q99500 1/20 0.46
▸ PPARD Q03181 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RARB P10826 4/20 0.45
▸ SMPD1 P17405 1/20 0.44
▸ PTGS2 P35354 1/20 0.43
▸ CYP19A1 P11511 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31527936 0.81 PPARD (0.46) ACACBRAB9APPARDPPARAMAPT
SCHEMBL31527952 0.77 LMNA (0.43) ACACBACACANPC1RAB9ASMN1; SMN2
SCHEMBL31527925 0.77 LMNA (0.46) ACACBNPC1RAB9ASMN1; SMN2TP53
SCHEMBL31527933 0.76 LMNA (0.42) ACACBNPC1RAB9ASMN1; SMN2TP53
SCHEMBL31527942 0.76 LMNA (0.42) ACACBNPC1RAB9ASMN1; SMN2TP53
SCHEMBL31527941 0.76 LMNA (0.40) ACACBACACARAB9ATP53MITF
SCHEMBL31528032 0.76 SCN9A (0.44) ACACBNPC1RAB9ASMN1; SMN2PPARD
SCHEMBL30880253 0.76 CYP2C9 (0.46) ACACBACACANPC1RAB9ASMN1; SMN2
SCHEMBL31528002 0.76 LMNA (0.44) ACACBNPC1RAB9ASMN1; SMN2TP53
SCHEMBL31527883 0.76 PPARD (0.41) ACACBRAB9APPARDPPARAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 — — CN claimed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 — — CN disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 ACACB 358/4885ACACA 144/4885NPC1 4019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback